Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Microbix Biosystems Inc., an innovator of biological products and technologies, announces the voting results from the Annual Meeting of Shareholders which was held on March 27, 2019.
$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1
Probiodrug AG announced its financial results for the twelve-month period ending December 31, 2018, prepared in accordance with German GAAP and on a voluntary basis, in accordance with IFRS as endorsed by the European Union.
Durham, NC-based Precision BioSciences set its initial public offering (IPO) price at $16 per share, raising $126.4 million. It began trading today on the Nasdaq under the ticker symbol DTIL.
The rumors speculated that AstraZeneca planned to acquire Aveo in the second quarter of this year in order to gain the company’s kidney cancer drug, Tivozanib.
GeoVax Labs, Inc., a biotechnology company developing human vaccines, announced its financial results for the year ended December 31, 2018.
Epigenomics AG announced the financial results for the year ended December 31, 2018.
Conference call and webcast, March 27, 2019 at 3pm CET (Frankfurt) / 10am EST (New York)
Genfit, with offices in Lille, France and Cambridge, Mass., launched its initial public offering (IPO) on the Nasdaq on March 27. Dean Hum, chief operating officer of Genfit, took time out to speak with BioSpace about the company, the IPO and elafibranor.
March has been a busy month for biopharma and medical device company initial public offerings. Here’s a look at the top IPO stories for the month.